MST Financial is proud to have supported Opthea Ltd (OPT.ASX) acting as Sole Lead Manager to the company’s A$227 million capital raising – the largest pre-Phase 3 readout biotech raise ever in Australia (ex CSL). The capital raising comprised of a A$10.0 million Institutional Placement and a $217.3 million accelerated non renounceable entitlement offer (ANREO).

Proceeds of the offer will be used to continue advancing clinical development of OPT-302 for the treatment of wet AMD, including progressing the Phase 3 clinical program, CMC (chemistry, manufacturing, and controls) activities and Biologics License application (BLA) preparations. OPT-302 treats wet AMD, the leading cause of irreversible blindness, by improving vision in patients.

#MSTFinancial #OptheaLtd #OPT #growthcapital #australianequities #ASX #finance #retinalspecialists #wetAMD #ophthalmology #macular #degeneration